Characteristics of Study Population (n = 26)
| Characteristic | Data |
|---|---|
| Number (n) | 26 (100%) |
| Age (y) | 74.6 ± 6.5 (61.9–84.6) |
| Gleason grade | |
| Median | 8 |
| Range | 7–9 |
| Laboratory values at C1D1 | |
| PSA (ng/mL) | 413 ± 719 (7 to 3,341) |
| Hemoglobin (g/dL) | 12.3 ± 1.0 (10.5 to 14.5) |
| Leukocyte count (103/μL) | 7.0 ± 1.9 (3.4 to 10.2) |
| Platelets (103/μL) | 247 ± 81 (131 to 480) |
| eGFR (mL/min/1.72 m2) | 76 ± 17 (44 to 105) |
| AST (U/L) | 29 ± 20 (13 to 97) |
| Alkaline phosphatase (U/L) | 149 ± 120 (40 to 543) |
| LDH (U/L) | 222 ± 59 (61 to 332) |
| Laboratory values at cycle 7, day 1 | |
| PSA (ng/mL) | 30 ± 48 (0 to 184) |
| Hemoglobin (g/dL) | 11.0 ± 1.0 (8.7 to 12.8) |
| Leukocyte count (103/μL) | 5.4 ± 1.1 (3.2 to 7.5) |
| Platelets (103/μL) | 183 ± 52 (94 to 305) |
| eGFR (mL/min/1.72m2) | 72 ± 17 (45 to 96) |
| AST (U/L) | 26 ± 9 (16 to 51) |
| Alkaline phosphatase (U/L) | 91 ± 55 (41 to 314) |
| LDH (U/L) | 214 ± 51 (150 to 338) |
| Site of disease | |
| Prostate bed | 9 (35%) |
| Bone | 21 (81%) |
| Lymph nodes | 20 (77%) |
| Liver | 2 (8%) |
| Other | 2 (8%) |
| Previous therapies | |
| Androgen-deprivation therapy | 26 (100%) |
| Abiraterone acetate | 16 (62%) |
| Enzalutamide | 17 (65%) |
| Chemotherapy | 19 (73%) |
| Docetaxel (first line) | 19 (73%) |
| Cabazitaxel (second line) | 8 (31%) |
| External radiation therapy | 17 (65%) |
eGFR = estimated glomerular filtration rate; AST = aspartate transaminase; LDH = lactate dehydrogenase.
Qualitative data are number of patients and percentage; continuous data are mean ± SD and range, except for Gleason grade.